Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the growth of Pacific Biosciences means decoding hundreds of pages on HiFi chemistry breakthroughs, consumable pull-through rates, and multi-million-dollar R&D programs. Those details hide in dense 10-K risk factors, 10-Q footnotes, and Form 4 insider trades. If you have ever wondered where to locate the next patent discussion or how much cash PACB is burning on its Revio sequencers, you know the challenge.
Stock Titan solves the problem. Our AI reads every Pacific Biosciences annual report 10-K simplified section, highlights revenue by product line, and flags fresh Pacific Biosciences 8-K material events explained within minutes of hitting EDGAR. Need the most recent Pacific Biosciences quarterly earnings report 10-Q filing? It arrives with an AI-powered summary of backlog trends and gross-margin shifts. Want to follow Pacific Biosciences insider trading Form 4 transactions? AG真人官方-time alerts surface each Pacific Biosciences Form 4 insider transactions real-time, so you can see when executives accumulate shares ahead of a new chemistry release. Our platform also clarifies the Pacific Biosciences proxy statement executive compensation tables in plain English, turning complex pay structures into actionable numbers.
Investors use these insights to:
- Compare R&D spending across quarters with our Pacific Biosciences earnings report filing analysis
- Monitor Pacific Biosciences executive stock transactions Form 4 before product launches
- Quickly verify supply-chain updates by understanding Pacific Biosciences SEC documents with AI
All filings鈥�10-K, 10-Q, 8-K, S-3, and more鈥攁rrive in one place, updated in real time and annotated by experts. Complex genomics disclosures are now clear, timely, and searchable.
Edmond de Rothschild Asset Management (France & Luxembourg) and Edmond de Rothschild Fund submitted Amendment No. 1 to Schedule 13G for Pacific Biosciences of California, Inc. (PACB), triggered by the 30 Jun 2025 measurement date.
- Aggregate shares: 13.37 million (EDRAM France) and 12.08 million (each Luxembourg entity).
- Ownership: 4.5 % of outstanding common stock for EDRAM France; 4.0 % for EDRAM Luxembourg and EdR Fund鈥攑lacing all filers below the 5 % reporting threshold.
- Voting/Dispositive power: Shared voting & dispositive authority over 12.08 million shares; sole dispositive power limited to 1.28 million shares; no sole voting power.
- The filers certify the stake is held in the ordinary course of business as passive investment managers, with no intent to influence control.
The filing confirms continued, but sub-5 %, institutional support from a prominent European asset manager without signaling activist involvement.
FAQ
What is the current stock price of Pacific Biosc (PACB)?
What is the market cap of Pacific Biosc (PACB)?
What is the core business of Pacific Biosciences?
How does Pacific Biosciences differentiate its sequencing technologies?
Which research applications are supported by Pacific Biosciences鈥� platforms?
How are Pacific Biosciences' solutions integrated into scientific research?
What regions contribute most to the company's revenue?
What benefits do advanced sequencing solutions provide to researchers?
How does Pacific Biosciences support clinical research?
What role does innovation play in the company鈥檚 strategy?
